Condition: Cardiogenic Shock · Extracorporeal Membrane Oxygenation · Vasopressors · Sponsor: Xiaotong Hou
The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.
This description comes directly from the study's public registry record.
Xiaotong Hou, MD · 010-64456631 · xt.hou@ccmu.edu.cn
Chenglong Li, MD · 86-18610846901 · cl_lee@163.com
Always discuss trial participation with your own doctor first.
| Beijing Anzhen Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06862700